ABSTRACT
Increasing waiting lists and a structural staff shortage are putting pressure on the health system. Because care production is lower than care demand, there is no longer competition. Competition is over and we are beginning to see the contours of the new health system. The new system takes health instead of care as its starting point by legally embedding health goals in addition to the duty of care. The new system is based on health regions, but does not require a regional health authority. It is based on health manifestos that include agreements about cooperation in good and bad times.
ABSTRACT
CASE: A 4-year-old girl sustained a traumatic atlantoaxial rotatory subluxation. She presented at the treating facility 8 months after injury with cervical deformity, neck pain, gait instability, and decreased cervical motion. Her delay in presentation was partially because of international Corona Virus of 2019 (COVID-19) travel restrictions. The case was successfully treated with halo traction, followed by halo vest immobilization. CONCLUSION: Chronic atlantoaxial rotatory fixation can be treated nonsurgically with closed reduction and halo traction, but is associated with operative risks. Optimal pin placement is challenging in the pediatric skull and may be improved with a preoperative or intraoperative computed tomography (CT) scan. Copyright © 2023 by The Journal of Bone and Joint Surgery, Incorporated.
ABSTRACT
The new coronavirus infection COVID-19 causes damage to many organs and systems, is a multi-organ disease. Many researchers are studying the relationship of the new coronavirus infection with polymorbid pathology, frailty, sarcopenia. The SARS-CoV-2 virus has the property of neurotropism, therefore, olfactory, taste disorders, as well as cognitive impairments can join the spectrum of clinical manifestations and consequences of the disease. Alzheimer's disease is the most common cause of dementia in the world. It is of interest that there is a link between the coronavirus infection and the development of cognitive impairment, including Alzheimer's disease.
ABSTRACT
Background: COVID-19 brought with it unknowns related to systemic sclerosis. Objective: To know the clinical evolution and prognosis of COVID-19 in a cohort of patients with systemic sclerosis. Methods: During the pandemic, we had digital contact with a cohort of 197 patients with SSc. If they had any condition that met the suspected definition of COVID-19, they underwent polymerase chain reaction testing for SARS-CoV-2;they were treated on an outpatient or hospital basis without interfering with their treatment. They followed their evolution every 24 hours until they became asymptomatic or died. Results: Thirteen patients (6.6%), nine diffuse cutaneous (dcSSc), and four limited cutaneous (lcSSc) developed COVID-19 during nine months of follow-up. The immunosuppressants used at the time of the disease were: mycophenolate mofetil, methotrexate, and prednisone, in low doses. Seven patients had interstitial lung disease (ILD). The main symptoms were chest pain, cough, dyspnea, dysgeusia, and anosmia, 1 with mild symptoms without pneumonia, 11 with mild pneumonia, and one with severe pneumonia that required hospital management. Only one (7.7%) presented severe pneumonia, was hospitalized, and died. Conclusions: COVID-19 disease in patients with SSc can be overcome in most cases, even when they are ILD and were using immunosuppressants at the time of infection with the SARS-CoV-2 virus. Copyright © 2023 Revista Medica del Instituto Mexicano del Seguro Social.
ABSTRACT
Background: In Mexico, diabetes mellitus (DM) and diseases cardiovascular, register an upward trend. Objective: To estimate the number of complications due to cardiovascular events (CVD) and complications derived from DM (CDM) accumulated in beneficiaries of the Mexican Institute of Social Security (IMSS) from 2019 to 2028, as well as the expense for medical and economic benefits in a scenario baseline and one of change in metabolic profile due to lack of medical follow-up during the COVID-19 pandemic. Material and methods: The number of CVD and CDM was estimated from 2019, with a 10-year risk projection using the ESC CVD Risk Calculator and United Kingdom Prospective Diabetes Study, considering risk factors registered in the institutional databases. Results: From 2019 to 2028, cumulative CVD cases were estimated at 2 million and those of CDM in 960 thousand, with an impact on medical spending of 439,523 million pesos and on the economic benefits of 174,085 millions. When considering the COVID-19 pandemic, CVD events and CDM increased by 589 thousand, with an increase in spending of 93,787 million pesos for medical care and 41,159 million for economic benefits. Conclusions: Without a comprehensive intervention in the management of CVD and CDM, the cost by both diseases will continue to increase, with financial pressures getting older. Copyright © 2023 Revista Medica del Instituto Mexicano del Seguro Social.
ABSTRACT
This case concerns a 54-year-old patient presenting to the Emergency Department with acute dyspnea and a loud stridor. Fiberscopy showed a large subglottic granuloma, most likely resulting from recent endotracheal intubation because of a severe COVID-19 infection. Increase in COVID-19 associated intubations may result in an increase of post-intubation granulomas.
ABSTRACT
INTRODUCTION: In February 2020, the World Health Organization (WHO) designated Covid-19 as a global pandemic, resulting in a growing population of individuals with a wide range of persistent symptoms after acute SARS-CoV-2 infection. According to the categories proposed by the WHO, the symptoms can be regarded as post-Covid if they developed during or after the Covid-19, continue >2 months and are not explained by an alternative diagnosis. Common persistent symptoms include fatigue, dyspnea, and decreased exercise capacity. Even though at diagnosis Covid- 19 has prominent hematologic manifestations, they mostly resolve after recovery from acute illness. We present a case of a 58-year-old male, without prior medical conditions, who developed a profound and prolonged anemia following mild Covid-19.
ABSTRACT
INTRODUCTION: In February 2020, the World Health Organization (WHO) designated Covid-19 as a global pandemic, resulting in a growing population of individuals with a wide range of persistent symptoms after acute SARS-CoV-2 infection. According to the categories proposed by the WHO, the symptoms can be regarded as post-Covid if they developed during or after the Covid-19, continue >2 months and are not explained by an alternative diagnosis. Common persistent symptoms include fatigue, dyspnea, and decreased exercise capacity. Even though at diagnosis Covid- 19 has prominent hematologic manifestations, they mostly resolve after recovery from acute illness. We present a case of a 58-year-old male, without prior medical conditions, who developed a profound and prolonged anemia following mild Covid-19.
ABSTRACT
The present report describes the case of a 23-year old pregnant woman who was in the 36.5th week of gestation of her second pregnancy. She was attended at the emergency room because of dry cough and progressive dyspnea, in association with headache and myalgia. The nasopharyngeal swab for SARS-CoV-2 polymerase chain reaction (PCR) was positive. Oxygen saturation and chest x-ray were normal. Laboratory tests showed elevated values of bilirubin, aminotransferases, alkaline phosphatase and lactic dehydrogenase, and mild thrombocytopenia. Shortly after being admitted she began with labor. Faced with the lack of progression, the termination of the pregnancy by cesarean section was decided. Arterial blood gases showed severe lactic acidosis. She never presented evidence of clinical signs of tissue hypoperfusion or sepsis that could explain it. The patient completed her postoperative period in the intensive care unit, undergoing supportive treatment. All laboratory parameters were normalized after 72 hours, evolving favorably from the clinical point of view. It was interpreted that she had a partial HELLP syndrome. Lactic acidosis is not a component of this syndrome. Nor can it be ascribed to a mild disease by SARS-Cov-2. It probably responded to a summation of causes, including hyperproduction of lactic acid during labor, as well as its reduced clearance because of liver dysfunction related to HELLP syndrome.
ABSTRACT
Background: COVID-19 can present neurological complications of the central nervous system. Ischemic-type strokes have been reported in this population. Neurological rehabilitation participates in the functional recovery and improvement of the quality of life of these patients.
ABSTRACT
Background: Intubation rates up to 33% have been found in patients diagnosed with COVID-19. Some cohorts have reported the presence of dyspnea in 84.1% of intubated patients, being this the only symptom associated with intubation. Oxygen saturation < 90% and increased respiratory rate have also been described as predictors of intubation.
ABSTRACT
BACKGROUND: As the number of case reports related to the new type of coronavirus (COVID-19) increases, knowledge of and experience with the virus and its complications also increase. Pleural complications are one relevant issue. We aimed in this study to analyze pleural complications, such as pneumothorax, pneumomediastinum, and empyema, in patients hospitalized with the diagnosis of COVID-19 pneumonia. METHODS: The files of patients who have pleural complications of COVID-19 pneumonia and were consulted about thoracic surgery between March 2020 and December 2020 were retrospectively reviewed. The data of the patients were analyzed according to age, sex, length of stay, treatment method for pleural complications, mortality, severity of COVID-19 pneumonia, tube thoracostomy duration, and presence of a mechanical ventilator. RESULTS: A total of 31 patients fulfilling the inclusion criteria were included in the study. There were 11 female (35.5%) and 20 male (65.5%) patients. The most common complication was pneumothorax in 20 patients (65%). The median duration of hospitalization was 22 days and the mortality rate was 71%. Mortality was significantly higher in patients on mechanical ventilation (p = 0.04). DISCUSSION: The mortality rate is very high in patients with pleural complications of COVID-19 pneumonia. Pneumothorax is a fatal complication in critically ill patients with COVID-19 pneumonia.
ABSTRACT
Background: Coronavirus disease 2019 (COVID-19) has provoked one of the greatest health crises of our time, which is why risk stratification at the time of hospitalization is essential to identify in good time patients with high morbidity and mortality risk. Dysnatremia as an independent predictor of mortality in patients with COVID-19 has recently become relevant. Objective: To find out if there is an association of dysnatremia with 28-day mortality, and as secondary objectives, its association with hospital stay, invasive mechanical ventilation (IMV) requirement and presence of acute kidney injury (AKI) during hospital stay. Material and methods: Retrospective, descriptive and analytical cohort study. All consecutive patients of 16 years or older of any gender, admitted to a third level hospital from March 1, 2020 to March 2021, who have a diagnosis of COVID-19 with positive PCR were included. Results: The study included a total of 722 patients. The prevalence of dysnatremia was as follows: 18 patients presented hypernatremia (2.49%) and 153 hyponatremia (21.19%). The presence of hypernatremia once sodium was corrected for glucose was associated with higher mortality (p < 0.05, OR 3.446;95% CI 1.776-6.688), an increased probability of presenting AKI (p <0.05, OR 2.985;95% CI 1.718-5.184) and a greater requirement for IMV (p < 0.05, OR 1.945;95% CI 1.701-5.098). Conclusions: Hypernatremia was associated with higher mortality, higher risk of presenting AKI and the requirement for IMV during hospitalization.
ABSTRACT
Background: A segment of children and adolescents with coronavirus disease 2019 (COVID-19) develops pneumonia and published evidence regarding its prognostic factors in this specific population is scarce. Objective: To characterize the survival of children and adolescents hospitalized for pneumonia related to COVID-19, as well as to evaluate prognostic factors for disease's outcomes. Material and methods: A cohort study was performed in Mexico and data from hospitalized children and adolescents with COVID-19 related pneumonia were analyzed. We used the Kaplan-Meier method to estimate survival functions and 95% confidence intervals (95% CI), as well as Cox proportional-hazards regressions to evaluate the association of the evaluated exposures with the outcomes of disease. Results: A total of 1423 patients were recruited for a follow-up of 15,188 person-days and the overall rate of in-hospital mortality (n = 208) was 13.7 per 1000 person-days. The survival function was 96.5% (95% CI 95.2-97.4%) and 69.3% (95% CI 63.9-74.0) of hospital stay, respectively. In multiple analysis, the history of immunosuppression was associated with an increased risk of a fatal outcome (hazard ratio [HR] = 2.70, IC 95% 1.38-5.30). Conclusions: We characterized the survival of a large cohort of children and adolescents with COVID-19 related pneumonia. The presented findings suggest that minors with a history of immunosuppression and pneumonia have an increased risk of fatal outcome.
ABSTRACT
Background: COVID-19 predominantly affects the respiratory system. However, persistent extrapulmonary (musculoskeletal and cardiovascular) conditions have been reported. Objective: To determine the most frequent cardiorespiratory and neuromusculoskeletal symptoms in patients with post-acute COVID 19 in a rehabilitation center. Material and methods: An observational, cross-sectional, descriptive and analytical study of post-acute COVID-19 patients was carried out. Clinical-demographic data, cardiorespiratory and neuromusculoskeletal symptoms were collected upon admission to the cardiopulmonary rehabilitation program. Descriptive statistics and association tests were used through the Chi squared test, taking p < 0.05 as significant. Results: 262 files were collected. The age was 49.9 +/- 11.5 years. There was a predominance of males (69.8%). The most prevalent symptoms, in the different degrees of severity (mild, moderate, severe and critical, respectively) were MRC 3 dyspnea (30.4%, 56.8%, 43.1% and 42.9%), weakness (60.9%, 59.5%, 56.9 % and 87.8%), and paresthesias (65.2%, 56.8%, 49.7% and 75.5%). SARS-CoV-2 critical infection was associated with a higher presentation of weakness (p < 0.01), paresthesias (p = 0.01), and dependency in activities of daily living (p < 0.01). Conclusions: The most frequent cardiorespiratory and neuromusculoskeletal symptoms in patients with post-acute COVID were dyspnea and paresthesias. Critical infection by SARS-CoV-2 was associated with a greater presentation of weakness, paresthesias and dependence on activities of daily living.
ABSTRACT
Background: The consequences of SARS-CoV-2 infection in patients with primary (now called "inborn errors of immunity") or secondary immunodeficiencies is still a matter of debate. There are few reports in the literature of patients with Good's syndrome and SARS-CoV-2 infection with variable outcomes. Clinical case: A 51-year-old male with diagnosis of Good's syndrome treated with intravenous human immunoglobulin (IVIG) at a replacement dose with application every 21 days and prophylaxis for P. jirovecii with trimethoprim/ sulfamethoxazole due to profound lymphopenia at expense of T CD4+ lymphocytes who presented initially mild disease (RT-PCR+) that progressed to pneumonia with acute respiratory failure and required advanced airway management and admission to the ICU with a fatal outcome due to superinfection after 14 days hospitalized. Conclusion: It has been documented in patients with humoral immunodeficiencies a better prognosis for developing less intense cytokine release syndrome. The alteration in cellular immunity, especially lymphopenia at the expense of CD4+ T lymphocytes, may be associated with a worse prognosis as the response against viruses is compromised as well as high susceptibility to superinfection by opportunistic agents such as P. aeruginosa and Mucor sp. For this reason, we must maintain close surveillance in patients with inborn errors of immunity with cellular defects, as is the case of patients with Good's syndrome who present with COVID-19.
ABSTRACT
The novel Severe Acute Respiratory Syndrome Coronavirus-2 has put an enormous pressure on health systems around the world. The large number of severe cases that had symptoms seemingly unrelated to the respiratory system, continues to create confusion. The digestive tract is not spared either. The most commonly reported digestive symptoms are nausea, vomiting, anorexia, diarrhea and, less frequently but with significant impact, gastrointestinal bleeding. The elderly population is the one more likely to develop severe anemia clinically expressed by hematemesis, melena or hematochezia. From our experience and as we concluded from literature, men confirmed with COVID-19 have a higher risk of developing digestive haemorrhage. The upper gastro-intestinal tract, defined as the digestive segment above the Treitz angle, is more often affected. The gastro-duodenal ulcers are the main cause found in COVID-19 patients with digestive bleeding. In addition, the patients with SARS-COV2 infection and gastro-intestinal bleeding most commonly associate with other comorbidities such as hypertension and diabetes.
ABSTRACT
BACKGROUND: COVID-19 aggravates lower urinary tract symptoms (LUTS) in patients with benign prostatic hyperplasia (BPH). The optimal treatment regimen for patients with this disease during the COVID-19 pandemic is still under question. OBJECTIVES: The aim of the All-Russian observational study of Afalaza in the Treatment of LUTS in pAtieNTs with BPH during COVID-19 (ATLANT) was to obtain additional data on the efficacy and safety of Afalaza in this patient group. METHOD: s. The study enrolled 73 men aged 46-65 years with LUTS and diagnosed BPH who suffered from COVID-19. All patients received Afalaza for 16 weeks. The dynamics of BHP indicators, erectile function, and quality of life were assessed after 4, 12, and 16 weeks of treatment. RESULTS: Patients with LUTS/BHP who suffered from COVID-19 had a decrease in the total IPSS score from 21.6+/-8.6 to 6.4+/-2.4 (-70.4%) points after 16 weeks of treatment. There was a direct correlation between COVID-19 duration (and beginning of therapy) and the severity of symptoms after Afalaza treatment. According to the subjective assessment of patients, there was a significant increase in the quality of life and erectile function after 16 weeks of treatment. 9 mild AEs were registered in 12.3% of patients and were unrelated to the study drug. CONCLUSIONS: Results show that Afalaza may be a perspective drug for the treatment of LUTS/BPH in patients with COVID-19 and be used for this urological disease in the current COVID-19 pandemic.
ABSTRACT
INTRODUCTION: Symptomatic coronavirus 2019 (COVID-19) infection usually presents with upper airway symptoms, but may lead to complications, such as pneumonia and involvement of other organs, or even death. Children often have a mild clinical course or may be asymptomatic, however, a severe complication of multisystem inflammatory syndrome has been described in rare cases. In severe COVID-19 infection, acute kidney injury may manifest even in children without comorbidities. The aim of this review is to present available data on renal involvement in pediatric COVID-19, and disease manifestations in children with underlying chronic kidney disease (CKD) or children receiving immunosuppressive medications due to kidney transplantation or glomerular disease. Although it could be assumed that children with CKD, including immunosuppressed patients, might be a high risk group for infection and severity of COVID-19 disease, this is not supported by current available data.